Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gedatolisib - Pfizer

Drug Profile

Gedatolisib - Pfizer

Alternative Names: PF-05212384; PF-5212384; PKI-587

Latest Information Update: 26 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Big Ten Cancer Research Consortium; Curie Institute; Eastchester Center for Cancer Care; Indiana University; Pfizer; University of Florida
  • Class Antineoplastics; Morpholines; Piperidines; Small molecules; Triazines; Urea compounds
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Breast cancer; Non-small cell lung cancer
  • Phase I Solid tumours
  • Discontinued Colorectal cancer; Endometrial cancer

Most Recent Events

  • 19 Nov 2019 Pfizer and Translational Breast Cancer Research Consortium withdraws the phase Ib/II GLACIER trial prior to enrolment in Breast cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV) (NCT03400254)
  • 28 Jul 2019 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
  • 17 Apr 2019 Phase-I/II clinical trials in Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03911973)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top